PUT PATIENTS FIRST
WITH OXLUMO® (lumasiran),
THE FIRST APPROVED THERAPY
FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)1-3
OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate (UOx) and plasma oxalate (POx) levels in children and adults. OXLUMO acts at the liver, the site of oxalate production. Overproduction of oxalate is the primary cause of disease manifestation in PH1.1
Tell Me About OXLUMO Tell Me About PH1
Person with PH1*
Person with PH1*
Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.
Treatment with OXLUMO led to powerful reduction in 24-hour urinary oxalate in patients with PH11
Treatment with OXLUMO resulted in a 53% reduction in 24-hour UOx excretion from baseline to month 6 (primary endpoint for ILLUMINATE-A) for OXLUMO compared to placebo in a double-blind clinical trial of 39 patients ≥6 years with eGFR ≥30 mL/min/1.73 m2.1,4,†
Least squares mean reduction averaged over months 3 through 6, corrected for BSA (OXLUMO, 65%; placebo, 12%); 95% CI: 45, 62; P<0.0001 vs placebo.
The dosing regimen for OXLUMO led to a rapid reduction in 24-hr UOx within 2 weeks, which was sustained through 24 months†,1,4,5
OXLUMO is a subcutaneous injection dosed by weight.
In ILLUMINATE-A: OXLUMO demonstrated reduction in 24-hr UOx excretion from baseline to month 6 compared to placebo.
WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?
Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.
There’s more to learn about OXLUMO
When you sign up, we will keep you informed with updates and resources.
Alnylam Assist™ provides support services for your patients throughout their treatment with OXLUMO.
Alnylam Assist™ includes patient services in key areas, including understanding insurance benefits and financial assistance options, helping ensure access to therapy, and providing PH1 disease education.
References: 1. OXLUMO (lumasiran) [Package Insert]. Cambridge, MA. Alnylam Pharmaceuticals. 2. Liebow A, Li X, Racie T, et al. J Am Soc Nephrol. 2017;28(2):494-503. 3. Hoppe B. Nat Rev Nephrol. 2012;8(8):467-475. 4. Garrelfs SF, Frishberg Y, Hulton SA, et al. N Engl J Med. 2021;384:1216-1226. doi:10.1056/NEJMoa2021712 5. Lieske J, Groothoff JW, Frishberg Y, et al. Presented at: National Kidney Foundation Spring Clinical Meetings; April 6-10, 2022; Boston, MA.